Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
February 23, 2015 at 15:42 PM EST
Immuno-oncology took center stage in the drug development world in 2014. But can this preeminence continue in 2015? In this interview, Stephen Dunn of LifeTech Capital outlines how companies are leveraging these therapies, and where investors should look for opportunity in the sector.
